Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T52227
(Former ID: TTDS00301)
|
|||||
Target Name |
Candida Thymidylate synthase (Candi TMP1)
|
|||||
Synonyms |
Tsase of Candida albicans; TS of Candida albicans; TMP1; Human recombinant thymidylate synthase; HrTS
Click to Show/Hide
|
|||||
Gene Name |
Candi TMP1
|
|||||
Target Type |
Successful target
|
[1] | ||||
Disease | [+] 9 Target-related Diseases | + | ||||
1 | Bacterial infection [ICD-11: 1A00-1C4Z] | |||||
2 | Colon cancer [ICD-11: 2B90] | |||||
3 | Colorectal cancer [ICD-11: 2B91] | |||||
4 | Endocarditis [ICD-11: BB40-BA42] | |||||
5 | Gram-positive bacterial infection [ICD-11: 1B74-1F40] | |||||
6 | Pleural mesothelioma [ICD-11: 2C26] | |||||
7 | Rectum cancer [ICD-11: 2B92] | |||||
8 | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | |||||
9 | Virus infection [ICD-11: 1A24-1D9Z] | |||||
Function |
Contributes to thede novo mitochondrial thymidylate biosynthesis pathway.
Click to Show/Hide
|
|||||
BioChemical Class |
Methyltransferase
|
|||||
UniProt ID | ||||||
EC Number |
EC 2.1.1.45
|
|||||
Sequence |
MTVSPNTAEQAYLDLCKRIIDEGEHRPDRTGTGTKSLFAPPQLRFDLSNDTFPLLTTKKV
FSKGIIHELLWFVAGSTDAKILSEKGVKIWEGNGSREFLDKLGLTHRREGDLGPVYGFQW RHFGAEYKDCDSDYTGQGFDQLQDVIKKLKTNPYDRRIIMSAWNPPDFAKMALPPCHVFC QFYVNFPTSSPDPNNPKQAKTAKPKLSCLLYQRSCDMGLGVPFNIASYALLTKMIAHVVD MDCGEFIHTLGDAHVYLDHIDALKEQFERIPKQFPKLVIKEERKNEIKSIDDFKFEDFEI VGYEPYPPIKMKMSV Click to Show/Hide
|
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Approved Drug(s) | [+] 9 Approved Drugs | + | ||||
1 | Capecitabine | Drug Info | Approved | Colorectal cancer | [2], [3] | |
2 | Ciprofloxacin XR | Drug Info | Approved | Bacterial infection | [4] | |
3 | Floxuridine | Drug Info | Approved | Solid tumour/cancer | [4], [5] | |
4 | Flucytosine | Drug Info | Approved | Endocarditis | [4], [6] | |
5 | Fluorouracil | Drug Info | Approved | Solid tumour/cancer | [3] | |
6 | Leucovorin/5-fluorouracil | Drug Info | Approved | Colon cancer | [3] | |
7 | Pemetrexed | Drug Info | Approved | Malignant pleural mesothelioma | [4], [7], [8], [9], [10] | |
8 | Raltitrexed | Drug Info | Approved | Rectal adenocarcinoma | [11], [3] | |
9 | Trifluridine | Drug Info | Approved | Virus infection | [12], [13] | |
Clinical Trial Drug(s) | [+] 6 Clinical Trial Drugs | + | ||||
1 | Nolatrexed | Drug Info | Phase 3 | Solid tumour/cancer | [14] | |
2 | Plevitrexed | Drug Info | Phase 2 | Gastric adenocarcinoma | [15], [16] | |
3 | Plevitrexed (R)-isomer | Drug Info | Phase 2 | Gastric adenocarcinoma | [16] | |
4 | UFT/leucovorin calcium | Drug Info | Phase 2 | Colorectal cancer | [17] | |
5 | NB1011 | Drug Info | Phase 1/2 | Breast cancer | [18] | |
6 | DFP-11207 | Drug Info | Phase 1 | Solid tumour/cancer | [19] | |
Discontinued Drug(s) | [+] 7 Discontinued Drugs | + | ||||
1 | EMITEFUR | Drug Info | Discontinued in Preregistration | Solid tumour/cancer | [20] | |
2 | Galocitabine | Drug Info | Discontinued in Phase 3 | Solid tumour/cancer | [21] | |
3 | FO-152 | Drug Info | Discontinued in Phase 2 | Solid tumour/cancer | [22] | |
4 | TT-62 | Drug Info | Discontinued in Phase 2 | Virus infection | [23] | |
5 | AG-331 | Drug Info | Discontinued in Phase 1 | Solid tumour/cancer | [24] | |
6 | DMPDDF | Drug Info | Terminated | Solid tumour/cancer | [25] | |
7 | Fosfluridine tidoxil | Drug Info | Terminated | Keratosis | [26] | |
Mode of Action | [+] 3 Modes of Action | + | ||||
Inhibitor | [+] 51 Inhibitor drugs | + | ||||
1 | Capecitabine | Drug Info | [27] | |||
2 | Ciprofloxacin XR | Drug Info | [28] | |||
3 | Floxuridine | Drug Info | [29] | |||
4 | Flucytosine | Drug Info | [6] | |||
5 | Fluorouracil | Drug Info | [30], [31], [32], [33] | |||
6 | Leucovorin/5-fluorouracil | Drug Info | [34], [35] | |||
7 | Pemetrexed | Drug Info | [1] | |||
8 | Raltitrexed | Drug Info | [36], [37] | |||
9 | Trifluridine | Drug Info | [38] | |||
10 | Nolatrexed | Drug Info | [39] | |||
11 | Plevitrexed | Drug Info | [40] | |||
12 | Plevitrexed (R)-isomer | Drug Info | [40] | |||
13 | DFP-11207 | Drug Info | [43] | |||
14 | EMITEFUR | Drug Info | [44] | |||
15 | Galocitabine | Drug Info | [45] | |||
16 | TT-62 | Drug Info | [47] | |||
17 | AG-331 | Drug Info | [48] | |||
18 | DMPDDF | Drug Info | [49] | |||
19 | Fosfluridine tidoxil | Drug Info | [50] | |||
20 | (6s)-5,6,7,8-Tetrahydrofolate | Drug Info | [51] | |||
21 | 1,3-propanediphosphonic acid | Drug Info | [52] | |||
22 | 1,4-Dithiothreitol | Drug Info | [51] | |||
23 | 10-Propargyl-5,8-Dideazafolic Acid | Drug Info | [51] | |||
24 | 2'-5'dideoxyuridine | Drug Info | [53] | |||
25 | 2'-Deoxycytidine-5'-Monophosphate | Drug Info | [51] | |||
26 | 2'-Deoxyguanosine-5'-Monophosphate | Drug Info | [51] | |||
27 | 2'-Deoxyuridine | Drug Info | [51] | |||
28 | 2'-deoxyuridylic acid | Drug Info | [51] | |||
29 | 2-bromophenol | Drug Info | [53] | |||
30 | 2-Sulfhydryl-Ethanol | Drug Info | [51] | |||
31 | 3-Amino-5,6-dihydro-2H-benzo[f]quinazolin-1-one | Drug Info | [54] | |||
32 | 3-DIPHENOL-6-NITRO-3H-BENZO[DE]ISOCHROMEN-1-ONE | Drug Info | [55] | |||
33 | 3-Methyl-2H-benzo[f]quinazolin-1-one | Drug Info | [54] | |||
34 | 4-CHLORO-3',3''-DIBROMOPHENOL-1,8-NAPHTHALEIN | Drug Info | [53] | |||
35 | 5,10-Methylene-6-Hydrofolic Acid | Drug Info | [51] | |||
36 | 5-Fluoro-2'-Deoxyuridine-5'-Monophosphate | Drug Info | [51] | |||
37 | 6-ETHYL-5-PHENYLPYRIMIDINE-2,4-DIAMINE | Drug Info | [55] | |||
38 | Ly231514 Tetra Glu | Drug Info | [51] | |||
39 | LY341770 | Drug Info | [51] | |||
40 | Methionine Sulfoxide | Drug Info | [55] | |||
41 | N,O-Didansyl-L-Tyrosine | Drug Info | [51] | |||
42 | N-Carboxymethionine | Drug Info | [51] | |||
43 | N-[Tosyl-D-Prolinyl]Amino-Ethanethiol | Drug Info | [51] | |||
44 | PREMETREXED | Drug Info | [56] | |||
45 | S,S-(2-Hydroxyethyl)Thiocysteine | Drug Info | [51] | |||
46 | Sp-722 | Drug Info | [51] | |||
47 | Sp-876 | Drug Info | [51] | |||
48 | Thymidine-5'-Phosphate | Drug Info | [51] | |||
49 | Tosyl-D-Proline | Drug Info | [51] | |||
50 | Uridine-5'-Monophosphate | Drug Info | [51] | |||
51 | ZD1604 | Drug Info | [33] | |||
Modulator | [+] 3 Modulator drugs | + | ||||
1 | UFT/leucovorin calcium | Drug Info | [41] | |||
2 | FO-152 | Drug Info | [46] | |||
3 | OVI-117 | Drug Info | [46] | |||
Binder | [+] 1 Binder drugs | + | ||||
1 | NB1011 | Drug Info | [42] |
Different Human System Profiles of Target | Top |
---|---|
Human Similarity Proteins
of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.
A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs
(Brief Bioinform, 21: 649-662, 2020).
Human Similarity Proteins
|
There is no similarity protein (E value < 0.005) for this target
|
Drug Property Profile of Target | Top | |
---|---|---|
(1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
||
(3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
||
(5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
||
"RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five |
Co-Targets | Top | |||||
---|---|---|---|---|---|---|
Co-Targets |
Target Profiles in Patients | Top | |||||
---|---|---|---|---|---|---|
Drug Resistance Mutation (DRM) |
Target-Related Models and Studies | Top | |||||
---|---|---|---|---|---|---|
Target Validation | ||||||
Target QSAR Model |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Updated clinical information on multitargeted antifolates in lung cancer. Clin Lung Cancer. 2009 Mar;10 Suppl 1:S35-40. | |||||
REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6799). | |||||
REF 3 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||||
REF 4 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||||
REF 5 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4801). | |||||
REF 6 | Antifungal agents: mode of action in yeast cells. Rev Esp Quimioter. 2006 Jun;19(2):130-9. | |||||
REF 7 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6837). | |||||
REF 8 | Pemetrexed in the treatment of advanced non-squamous lung cancer. Lung Cancer. 2009 Nov;66(2):141-9. | |||||
REF 9 | 2004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4. | |||||
REF 10 | Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed. Lung Cancer. 2011 Oct;74(1):132-8. | |||||
REF 11 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7403). | |||||
REF 12 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8697). | |||||
REF 13 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 074311. | |||||
REF 14 | ClinicalTrials.gov (NCT00012324) Nolatrexed Dihydrochloride Compared With Doxorubicin in Treating Patients With Recurrent or Unresectable Liver Cancer. U.S. National Institutes of Health. | |||||
REF 15 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8278). | |||||
REF 16 | Clinical pipeline report, company report or official report of plevitrexed. | |||||
REF 17 | A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer. Br J Cancer. 2008 Sep 2;99(5):722-6. | |||||
REF 18 | ClinicalTrials.gov (NCT00248404) NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS). U.S. National Institutes of Health. | |||||
REF 19 | ClinicalTrials.gov (NCT02171221) Phase I Study of Oral DFP-11207 in Solid Tumors. U.S. National Institutes of Health. | |||||
REF 20 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002454) | |||||
REF 21 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002535) | |||||
REF 22 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003064) | |||||
REF 23 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002433) | |||||
REF 24 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003304) | |||||
REF 25 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004963) | |||||
REF 26 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019549) | |||||
REF 27 | UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res. 2005 Feb 1;11(3):1226-36. | |||||
REF 28 | Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer. 2003 Feb 20;103(5):587-99. | |||||
REF 29 | Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells. Br J Pharmacol. 1999 Aug;127(8):1777-86. | |||||
REF 30 | The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors. Cancer Chemother Pharmacol. 2004 Apr;53(4):296-304. | |||||
REF 31 | Association of gastric and intestinal phenotypic marker expression of gastric carcinomas with tumor thymidylate synthase expression and response to... J Cancer Res Clin Oncol. 2003 Dec;129(12):683-90. | |||||
REF 32 | Thymidylate synthase expression in patients with colorectal carcinoma using a polyclonal thymidylate synthase antibody in comparison to the TS 106 monoclonal antibody. J Histochem Cytochem. 2000 Jun;48(6):755-60. | |||||
REF 33 | Acquisition of resistance to anticancer agents by overproduction of target enzymes. Nippon Rinsho. 1997 May;55(5):1030-7. | |||||
REF 34 | Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance. Mol Cancer Ther. 2009 May;8(5):1037-44. | |||||
REF 35 | Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward Cancer Biol Ther. 2008 Jul;7(7):986-94. | |||||
REF 36 | DNA damage and homologous recombination signaling induced by thymidylate deprivation. Biochem Pharmacol. 2008 Oct 15;76(8):987-96. | |||||
REF 37 | Cellular pharmacology of MTA: a correlation of MTA-induced cellular toxicity and in vitro enzyme inhibition with its effect on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells. Semin Oncol. 1999 Apr;26(2 Suppl 6):48-54. | |||||
REF 38 | Trifluorothymidine induces cell death independently of p53. Nucleosides Nucleotides Nucleic Acids. 2008 Jun;27(6):699-703. | |||||
REF 39 | A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (nolatrexed dihydrochloride) given by 10-day oral administration. Br J Cancer. 1999 Feb;79(5-6):915-20. | |||||
REF 40 | Cooperative inhibition of human thymidylate synthase by mixtures of active site binding and allosteric inhibitors. Biochemistry. 2007 Mar 13;46(10):2823-30. | |||||
REF 41 | Leucovorin enhancement of the effects of the fluoropyrimidines on thymidylate synthase. Cancer. 1989 Mar 15;63(6 Suppl):1008-12. | |||||
REF 42 | Kinetic properties of human thymidylate synthase, an anticancer drug target. Biochem Biophys Res Commun. 2003 Jul 25;307(2):297-300. | |||||
REF 43 | National Cancer Institute Drug Dictionary (drug id 762603). | |||||
REF 44 | Antitumor activity of fluoropyrimidines and thymidylate synthetase inhibition. Jpn J Cancer Res. 1991 Apr;82(4):476-82. | |||||
REF 45 | The role of thymidylate synthase in cellular regulation. Adv Enzyme Regul. 1996;36:143-63. | |||||
REF 46 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2642). | |||||
REF 47 | TECHNOLOGY, PRODUCTS, MARKETS AND SERVICE OPPORTUNITIES. Future Oncology. AUGUST 1995. VOLUME 1, NUMBER 4. | |||||
REF 48 | Phase I trial of the thymidylate synthase inhibitor AG331 as a 5-day continuous infusion. Clin Cancer Res. 1996 Oct;2(10):1685-92. | |||||
REF 49 | Folate analogues. 32. Synthesis and biological evaluation of 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid and related compounds. J Med Chem. 1989 Jun;32(6):1284-9. | |||||
REF 50 | Selective protection by uridine of growth inhibition by 5-fluorouracil (5FU) mediated by 5FU incorporation into RNA, but not the thymidylate synthase mediated growth inhibition by 5FU-leucovorin. Nucleosides Nucleotides Nucleic Acids. 2008 Jun;27(6):733-9. | |||||
REF 51 | How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. | |||||
REF 52 | Novel approaches for targeting thymidylate synthase to overcome the resistance and toxicity of anticancer drugs. J Med Chem. 2010 Sep 23;53(18):6539-49. | |||||
REF 53 | DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. | |||||
REF 54 | Benzoquinazoline inhibitors of thymidylate synthase: enzyme inhibitory activity and cytotoxicity of some sulfonamidobenzoylglutamate and related de... J Med Chem. 1993 Oct 29;36(22):3464-71. | |||||
REF 55 | The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. | |||||
REF 56 | Dual inhibitors of thymidylate synthase and dihydrofolate reductase as antitumor agents: design, synthesis, and biological evaluation of classical ... J Med Chem. 2006 Feb 9;49(3):1055-65. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.